Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial

Ciruelos, E. M.Villagrasa, P.Oliveira, M.Pernas Simon, S.Cortes, J.Vazquez, S.Martinez, N.Perello, A.Bermejo De Las Heras, B.Martinez, E.Garau Llinas, I.Mele Olive, M.Montano, A.Vega, E.Cantos, B.Echarri, M. J.Pascual, T.Celiz, P.Gonzalez-Farre, X.Prat, A.2025-01-072025-01-072020-05-010923-7534https://hdl.handle.net/10668/27212enPalbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trialconference outputopen access10.1016/j.annonc.2020.03.2801569-8041http://www.annalsofoncology.org/article/S0923753420363596/pdf538879300160